Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations

NCT03581292 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

38

Enrollment

NIH

Sponsor class

Conditions

Anaplastic Astrocytoma
Glioblastoma
Malignant Glioma

Interventions

RADIATION: Radiation Therapy
DRUG: Temozolomide
DRUG: Veliparib

Sponsor

National Cancer Institute (NCI)